타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TNFi (TNFi, Tumor Necrosis Factor inhibitor, TNFi (Tumor Necrosis Factor inhibitor) medication) Bristol-Myers Squibb·Polyarticular Course Juvenile Idio… 134 trials | ||
|---|---|---|---|
Overview Program | Humira (adalimumab) | Enbrel (etanercept) | TNFi (Tumor Necrosis Factor inhibitor) medication |
Overview Company | AbbVie | Amgen / Pfizer | Bristol-Myers Squibb |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | TNF (decoy receptor) | Polyarticular Course Juvenile Idiopathic |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | RA, PsA, AS, plaque psoriasis, JIA | Polyarticular Course Juvenile Idiopathic Arthritis (JIA) |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | novel object recognition test | novel ADAM17 inhibitor drugs to block soluble TNF-α production in inflammatory diseases | — |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. | Anti-drug antibodies (lower vs mAb TNF inhibitors), non-TNF pathways. | — |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). | Etanercept is a dimeric fusion protein of human p75 TNF receptor linked to IgG1 Fc; it binds TNF-α and lymphotoxin-α, preventing receptor activation and downstream NF-κB inflammatory signaling. | Targeting specific cytokine pathway |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). | DAS28, PASI, CRP. | biomarker for the effectiveness of mainly abatacept and other biologic disease-modifying antirheumatic drugs |
Toxicology Species | Cynomolgus monkey | — | — |
Toxicology Animal (cat.) | NHP | — | — |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. | — |
Toxicology CRS | N/A | N/A | — |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | — | Rat | — |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 3개 · 임상 갱신 필요 3개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | TNFi (TNFi, Tumor Necrosis Factor inhibitor, TNFi (Tumor Necrosis Factor inhibitor) medication) Bristol-Myers Squibb·Polyarticular Course Juvenile Idio… 134 trials | ||
|---|---|---|---|
Overview Program | Humira (adalimumab) | Enbrel (etanercept) | TNFi (Tumor Necrosis Factor inhibitor) medication |
Overview Company | AbbVie | Amgen / Pfizer | Bristol-Myers Squibb |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | TNF-α | TNF (decoy receptor) | Polyarticular Course Juvenile Idiopathic |
Overview Indication | Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA | RA, PsA, AS, plaque psoriasis, JIA | Polyarticular Course Juvenile Idiopathic Arthritis (JIA) |
Overview Phase | APPROVED | APPROVED | PHASE_3 |
Overview Status | APPROVED | APPROVED | RECRUITING |
Overview Content status | Curated Core | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | FDA approved | Investigational |
Positioning Key differentiator | novel object recognition test | novel ADAM17 inhibitor drugs to block soluble TNF-α production in inflammatory diseases | — |
Positioning Known limitation | Anti-drug antibodies, TNF-independent inflammation, and immunogenicity lowering trough levels. | Anti-drug antibodies (lower vs mAb TNF inhibitors), non-TNF pathways. | — |
MoA Mechanism | Adalimumab binds specifically to TNF-α and blocks its interaction with p55 and p75 cell-surface TNF receptors, neutralizing TNF-mediated inflammatory cascades (IL-6, adhesion molecules, acute-phase proteins). | Etanercept is a dimeric fusion protein of human p75 TNF receptor linked to IgG1 Fc; it binds TNF-α and lymphotoxin-α, preventing receptor activation and downstream NF-κB inflammatory signaling. | Targeting specific cytokine pathway |
MoA Biomarker | CRP, ESR, disease-specific scores (DAS28, PASI, Mayo for IBD). | DAS28, PASI, CRP. | biomarker for the effectiveness of mainly abatacept and other biologic disease-modifying antirheumatic drugs |
Toxicology Species | Cynomolgus monkey | — | — |
Toxicology Animal (cat.) | NHP | — | — |
Toxicology Major finding | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. | — |
Toxicology CRS | N/A | N/A | — |
Clinical Safety signal | Serious infections (TB reactivation, invasive fungal), malignancy risk signal, injection-site reactions, and rare demyelinating events. | Injection-site reactions, infections, rare demyelination and lupus-like syndrome. | — |
Clinical Program phase | APPROVED | APPROVED | PHASE_3 |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts |
Preclinical Animal (cat.) | — | Rat | — |
추천 비교
추천 비교